Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
MC Cid, SH Unizony, D Blockmans… - Annals of the …, 2022 - ard.bmj.com
Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in
pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor …
pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor …
Functionally heterogenous macrophage subsets in the pathogenesis of giant cell arteritis: novel targets for disease monitoring and treatment
I Esen, WF Jiemy, Y van Sleen… - Journal of Clinical …, 2021 - mdpi.com
Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that affects adults above
50 years of age. In GCA, circulating monocytes are recruited to the inflamed arteries. With …
50 years of age. In GCA, circulating monocytes are recruited to the inflamed arteries. With …
New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?
Giant cell arteritis is a primary granulomatous vasculitis characterised by a strict tissue
tropism for large and medium-size vessels, occurring in people older than 50 years …
tropism for large and medium-size vessels, occurring in people older than 50 years …
[PDF][PDF] A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 …
Objective Macrophages mediate inflammation, angiogenesis, and tissue destruction in giant
cell arteritis (GCA). Serum levels of the macrophage‐associated protein YKL‐40 (chitinase 3 …
cell arteritis (GCA). Serum levels of the macrophage‐associated protein YKL‐40 (chitinase 3 …
Biologic therapies for giant cell arteritis
R Harrington, SA Al Nokhatha… - Biologics: Targets and …, 2021 - Taylor & Francis
Glucocorticoids have been the mainstay of treatment in giant cell arteritis (GCA) for the past
70 years. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) have …
70 years. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) have …
Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar proteinosis phenotype but does alter lung surfactant …
DJ Corkill, AN Hunt, MJ Hinrichs, N White… - Clinical …, 2021 - portlandpress.com
Granulocyte macrophage colony stimulating factor (GM-CSF) is a key participant in, and a
clinical target for, the treatment of inflammatory diseases including rheumatoid arthritis (RA) …
clinical target for, the treatment of inflammatory diseases including rheumatoid arthritis (RA) …
Immune signatures in chronic inflammatory diseases: Focus on metabolism and IL-6
I Esen - 2023 - research.rug.nl
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are inflammatory rheumatic
diseases that may develop with aging. GCA is one of the most common forms of vasculitis …
diseases that may develop with aging. GCA is one of the most common forms of vasculitis …
Macrophage diversity in the pathogenesis of vasculitides: implications for diagnosis and treatment
WF Jiemy - 2021 - research.rug.nl
Giant cell arteritis (GCA) and anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) are diseases marked by inflammation of blood vessels. Vascular damage …
vasculitis (AAV) are diseases marked by inflammation of blood vessels. Vascular damage …
[PDF][PDF] Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar proteinosis (PAP) phenotype but does alter …
DJ Corkill, AN Hunt, MJ Hinrichs, N White, M Rebelatto… - pdfs.semanticscholar.org
Granulocyte macrophage colony stimulating factor (GM-CSF) is a key participant in, and a
clinical target for, the treatment of inflammatory diseases including rheumatoid arthritis (RA) …
clinical target for, the treatment of inflammatory diseases including rheumatoid arthritis (RA) …